Determining value of Coordinated Registry Networks (CRNs): a case of transcatheter valve therapies
BMJ Surgery, Interventions, & Health Technologies · 2019
DOI: 10.1136/bmjsit-2019-000003 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMJ Surgery, Interventions, & Health Technologies, 2019. Verfasst von Gregory Pappas und 24 weiteren Autor:innen. Beteiligte Einrichtung: Food and Drug Administration, Department of Health and Human Services, Silver Spring, Maryland, USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The Transcatheter Valve Therapy (TVT) Coordinated Registry Network (CRN) supported 23 regulatory decisions and ensured evidence-based evaluation of the application of TVT technology. However, there are cost concerns that require value assessment of the TVT CRN compared with traditional study designs.
Objectives
We aimed to determine the value created by the TVT CRN based on (1) Return on investment (ROI), (2) Time saved (TS) in conducting necessary regulatory studies.
Methods
For both ROI and TS analyses, we compared studies that used the TVT CRN with those that would have been required if the registry did not exist (counterfactual studies). To estimate ROI, we accounted for the costs of investment and gain from investment. Both the counterfactual costs and length of studies were projected using design specifications determined by US Food and Drug Administration (FDA) reviewers.
Results
We identified 21 studies using the TVT CRN (supporting 23 FDA decisions) that generated evidence on TVT for three device manufacturers. ROI is estimated to be greater than 550%. TS by using the CRN ranged from months to years.
Conclusions
The CRN method to evidence generation creates value for manufacturers and the broader device ecosystem, demonstrated with this example of the TVT CRN. The public health benefits of evidence created by this CRN outweighs the difference in data quality between traditional clinical studies and the CRN method.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Food and Drug Administration, Department of Health and Human Services, Silver Spring, Maryland, USA.
- Pharmacoepidemiology, Johnson and Johnson Services Inc, New Brunswick, New Jersey, USA.
- Interventional Cardiology, University of Colorado Denver, Denver, Colorado, USA.
- Mercy Health, Chesterfield, Missouri, USA.
- American College of Cardiology, Washington, District of Columbia, USA.
- Cardiovascular Research Foundation, Columbia University / New York-Presbyterian Hospital, New York City, New York, USA.
ORCID-Profile: Gregory Pappas
Zitieren
APA
Pappas, G., Berlin, J., Avila-Tang, E., Carroll, J., Drozda, J., Dumont, D., Gross, T., Hewitt, K., Kirtane, A., Kong, D., Krucoff, M., Lashinger, J., Lew, N., Mack, M., Masoudi, F., Marinac-Dabic, D., Mehran, R., Normand, S. L., Quin, E., …, & Ziegler, T. (2019). Determining value of Coordinated Registry Networks (CRNs): a case of transcatheter valve therapies. BMJ Surgery, Interventions, & Health Technologies. https://doi.org/10.1136/bmjsit-2019-000003
Vancouver
Pappas G, Berlin J, Avila-Tang E, Carroll J, Drozda J, Dumont D, et al. Determining value of Coordinated Registry Networks (CRNs): a case of transcatheter valve therapies. BMJ Surgery, Interventions, & Health Technologies. 2019. doi:10.1136/bmjsit-2019-000003
BibTeX
@article{Pappas2019,
author = {Pappas, Gregory and Berlin, Jesse and Avila-Tang, Erika and Carroll, John and Drozda, Joseph and Dumont, Douglas and Gross, Thomas and Hewitt, Kathleen and Kirtane, Ajay and Kong, David and Krucoff, Mitchell and Lashinger, John and Lew, Nellie and Mack, Michael and Masoudi, Fred and Marinac-Dabic, Danica and Mehran, Roxanna and Normand, Sharon-Lise and Quin, Elizabeth and Resnic, Fred and Sedrakyan, Art and Waksman, Ronald and Wood, Larry and Wu, Changfu and Ziegler, Tianay},
title = {Determining value of Coordinated Registry Networks (CRNs): a case of transcatheter valve therapies},
journal = {BMJ Surgery, Interventions, & Health Technologies},
year = {2019},
doi = {10.1136/bmjsit-2019-000003}
}
EUVIMED